Outsourced Pharma White Papers

  1. Leveraging Efficiency From CLD To Clinical Manufacturing Of mAbs 2/4/2026

    Discover how our efficient strategies can propel your mAb from discovery to clinical manufacturing in as little as 18 months.

  2. Continuous Flow — An Emerging Alternative 3/17/2026

    Gain insights on transitioning from batch to continuous flow processes, the benefits of continuous flow chemistry, and ensuring regulatory compliance with Quality by Design (QbD) principles.

  3. Modern Modeling Tools For Small Molecule Solid Dose Manufacturing 3/10/2025

    Data-driven modeling techniques can enhance scale-up processes, streamline production, and help companies navigate the complexities of modern drug development with greater precision and reliability.

  4. Building Local Biomanufacturing Capacity In South Africa 2/11/2025

    Biovac evolved from a vaccine supplier to a biopharmaceutical innovator, providing a blueprint for expanding Africa's vaccine manufacturing capacity. Gain valuable insights from their journey.

  5. Vial Breakage During Lyophilization: Root Causes And Mitigation 10/16/2024

    Learn how controlling freezing rates, using specialized vials, and employing optimized stoppering techniques can reduce the risk of vial breakage during lyophilization and ensure high product quality.

  6. Streamlining Early Drug Development: Efficient Synthesis Of Highly Potent Compounds 5/6/2026

    Discover how risk‑based, phase‑appropriate synthesis enables safe, efficient production of highly potent compounds while balancing speed, worker safety, and regulatory readiness in early development.

  7. Accelerating Drug Development: Solid State Chemistry And Strategic Outsourcing 5/6/2026

    Discover how phase‑appropriate solid‑state chemistry and strategic outsourcing reduce risk, speed development timelines, and enable confident solid‑form selection for complex small‑molecule programs.

  8. How To Design And Evaluate Bispecific Antibodies (BsAbs)? 11/25/2025

    Bispecific antibodies combine two antigen-binding sites to enhance efficacy and safety. Their design requires structural strategy, MOA-based evaluation, and rigorous screening for optimal therapeutic performance.

  9. Precision By Design: Drug Innovation Through Structure-Based Drug Design (SBDD) 5/6/2026

    Leverage structure-based drug design to gain deeper molecular insights, prioritize high-potential candidates, and accelerate your path from discovery to clinic.

  10. Redefining Biomanufacturing For Personalized Cancer Vaccines 4/24/2026

    Personalized cancer vaccines need fast, flexible manufacturing. Cell‑free synthetic DNA enables rapid, small‑batch mRNA production, supporting individualized therapies beyond plasmid‑based limits.